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Summary
The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-
overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab
response is poorly understood. Here we report that PTEN activation contributes to trastuzumab’s antitumor activity.
Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine
phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzu-
mab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to
trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab
resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting
therapies could overcome this resistance.
Introduction et al., 2002), the induction of G1 arrest and the cyclin-dependent
kinase inhibitor p27kip1 (Sliwkowski et al., 1999), and the inhibition
Overexpression of ErbB2, a 185 kDa membrane receptor tyro- of ErbB2 ectodomain cleavage (Molina et al., 2001). Despite
sine kinase, is found in 20%–30% of human breast cancers and these and other reported functions that result from ErbB2 down-
many other cancer types (Slamon et al., 1987; Yu and Hung, regulation (Petit et al., 1997), the mechanism of trastuzumab’s
2000). ErbB2 overexpression leads to a very aggressive cancer antitumor activity remains a fundamental question to be clearly
phenotype and poor patient survival (Slamon et al., 1987; Yu addressed (Baselga and Albanell, 2001).
and Hung, 2000). Numerous efforts have been directed at devel- As the only FDA-approved therapeutic antibody for meta-
oping ErbB2-targeting cancer therapies (Bange et al., 2001). static breast cancer, trastuzumab has demonstrated durable
One successful example is the recombinant humanized anti- responses as a single agent and striking therapeutic efficacy
in combination with other chemotherapeutics (Cobleigh et al.,ErbB2 monoclonal antibody trastuzumab (Herceptin) that spe-
cifically binds to the extracellular domain of ErbB2 (Cho et al., 1999; Esteva et al., 2002; Seidman et al., 2001; Slamon et
al., 2001). However, less than 35% of patients with ErbB2-2003; Shepard et al., 1991). The currently known mechanisms
underlying trastuzumab’s antitumor activity include the down- overexpressing metastatic breast cancer respond to trastuzu-
mab as a single agent, whereas 5% of patients suffer fromregulation of p185ErbB2 and the subsequent inhibition of its down-
stream PI3K-Akt signaling pathway (Hudziak et al., 1989; Yakes severe side effects (e.g., cardiac dysfunction) and 40% of pa-
S I G N I F I C A N C E
Trastuzumab is an excellent model of rationally designed targeted cancer treatment. However, the overall trastuzumab response
rate is low and the causes of trastuzumab resistance are poorly understood. Here, our data introduce the new concept that a rapid
PTEN activation, before downregulation of ErbB2, is a novel mechanism underlying the antitumor activity of trastuzumab, whereas
PTEN deficiency is significantly associated with trastuzumab resistance in breast cancer patients. PTEN deficiencies were reported
in 50% of breast cancers. Our findings have direct implications in the treatment of these patients with the worst clinical outcomes.
PTEN deficiency may serve as an indicator for trastuzumab resistance that requires PI3K-targeting combination treatment to overcome
this resistance.
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tients experience other adverse effects from trastuzumab treat- (Figure 1B). Contrarily, the p85 subunit of PI3K had a transiently
increased association with the ErbB2 complex (Figure 1C),ment (Cobleigh et al., 1999; Vogel et al., 2002). Thus, there is
an urgent need to identify patients who are unlikely to respond which paralleled a moderate increase of ErbB2 tyrosine phos-
phorylation by short-time trastuzumab treatment (Figure 1A).to trastuzumab treatment to spare them the potential side ef-
fects and unnecessary cost. More importantly, trastuzumab re- The apparently paradoxical results indicate that, different from
the previously reported mechanism of Akt dephosphorylationsistance-conferring factors may serve as molecular targets for
overcoming trastuzumab resistance. Unfortunately, information that is dependent on ErbB2 downregulation or PI3K inhibition
(Hudziak et al., 1989; Yakes et al., 2002), the rapid Akt dephos-on the mechanisms of trastuzumab resistance in breast cancer
cells is limited. Currently, there is no clinically verified factor phorylation by 1 hr trastuzumab treatment was not due to PI3K
inhibition, nor by ErbB2 degradation and dephosphorylation,that can be used to predict trastuzumab resistance (Albanell
and Baselga, 2001). but by some other novel mechanism.
The tumor suppressor PTEN is a dual-phosphatase thatPTEN (MMAC1/TEP) is a dual phosphatase that mainly
dephosphorylates position D3 of membrane phosphatidylino- negatively regulates Akt activity (Cantley and Neel, 1999; Di
Cristofano and Pandolfi, 2000; Leslie and Downes, 2002). Wesitol-3,4,5 trisphosphate (PI3,4,5P3), which is the site for
recruiting the plecstrin-homology domain of Akt to the cell mem- thus asked whether PTEN activation may possibly be involved in
the trastuzumab-mediated rapid Akt dephosphorylation beforebrane (Parsons and Simpson, 2003). Since phosphatidylinositol
3-kinase (PI3K) catalyzes the production of PI3,4,5P3 (Cantley, PI3K inhibition and ErbB2 downregulation. We examined the
PTEN phosphatase activity in untreated and trastuzumab-2002), PTEN antagonizes this PI3K function and negatively regu-
lates Akt activities. Loss of PTEN function due to PTEN muta- treated (20 or 60 min) SKBr3 cells after immunoprecipitation
(IP) of a similar amount of PTEN using the Ab-2 PTEN antibodytions, PTEN haploinsufficiency from LOH at the PTEN locus,
and epigenetic downmodulation of PTEN have been reported (Figure 1D, insert). Compared with untreated cells, 20 min trastu-
zumab treatment dramatically increased PTEN activity, whichin nearly 50% of breast cancers and in many other cancer types
(Li et al., 1997; Mutter et al., 2000; Parsons and Simpson, 2003; continued to increase 60 min after treatment (Figure 1D). Similar
results were obtained using another PTEN antibody (A2B1, notTeng et al., 1997; Whang et al., 1998). Restoration of PTEN
expression in PTEN null cells inhibits Akt activities and tumor shown). Therefore, trastuzumab treatment indeed led to a rapid
increase of PTEN phosphatase activity that could account forformation (Li and Sun, 1998; Lu et al., 1999). Therefore, PTEN
is an important tumor suppressor gene. However, possible func- the rapid Akt dephosphorylation before ErbB2 is downregulated
and before PI3K is inhibited.tional interactions of PTEN activity with ErbB2 receptor tyrosine
kinase signaling and potential roles for PTEN in the antitumor Membrane-associated PTEN is known to be biologically ac-
tive in cells (Comer and Parent, 2002; Iijima and Devreotes,activity of trastuzumab have never been explored. In this report,
we demonstrate that PTEN activation is a novel mechanism 2002; Wu et al., 2000). To investigate whether PTEN activation
by trastuzumab is due to recruitment of PTEN to its biologicallyunderlying trastuzumab’s antitumor activity and that PTEN loss
renders ErbB2-overexpressing breast cancer resistant to trastu- active subcellular location, we examined whether membrane
localization of PTEN is increased by trastuzumab. After treatingzumab-based therapy.
BT474 cells with or without trastuzumab for 20 min, we sepa-
rated membrane bound proteins from cytosolic proteins in cellResults
lysates and examined PTEN proteins by Western blotting (Figure
1E). In the untreated cells, the majority of PTEN protein was inTrastuzumab activates PTEN in breast cancer cells
In our investigation of the mechanisms of trastuzumab’s antitu- the cytosolic pool of the lysates, while a very low level of PTEN
was detected in the membrane bound pool. This is consistentmor function, we observed that 20 hr trastuzumab treatment
of BT474 and SKBr3 human breast cancer cell lines over- with the notion that PTEN is functionally inactivated in ErbB2-
overexpressing cancer cells (Cantley and Neel, 1999; Lu et al.,expressing endogenous ErbB2 led to ErbB2 downregulation,
dephosphorylation, and receptor internalization as expected 1999). However, upon trastuzumab treatment, PTEN protein in
the membrane bound pool was noticeably enriched. Interest-(Lee et al., 2002). However, 1 hr trastuzumab treatment (2–10
g/ml) did not induce ErbB2 downregulation, dephosphoryla- ingly, the MCF7 breast cancer cells with normal ErbB2 expres-
sion had more membrane bound PTEN than the ErbB2-overex-tion, and receptor internalization (Figure 1A and Supplemental
Figure S1 at http://www.cancercell.org.cgi/content/full/6/2/117/ pressing BT474 cells before trastuzumab treatment, yet a further
increase of the membrane bound PTEN was not induced byDC1). Surprisingly, 1 hr trastuzumab treatment quickly reduced
the level of phosphorylated and activated Akt in BT474 and trastuzumab in MCF7 cells (Supplemental Figure S2). These
data suggest that in ErbB2-overexpressing breast cancer cells,SKBr3 cells while the Akt protein level remained unchanged
(Figure 1A). It is known that Akt is constitutively activated in trastuzumab treatment specifically facilitates PTEN localization
to the cell membrane, where this phosphatase is active andErbB2-overexpressing cancer cells and Akt is inhibited after
ErbB2 downregulation by trastuzumab, which is critical for tras- functions to dephosphorylate PIP3 to PIP2, leading to Akt de-
phosphorylation.tuzumab’s antitumor effect (Ignatoski et al., 2000; Yakes et al.,
2002; Zhou et al., 2000). However, the rapid Akt dephosphoryla- PTEN binds to the cellular membrane through its C2 domain
and there are two tyrosine phosphorylation sites in the C2 do-tion by trastuzumab before ErbB2 downregulation has not been
reported nor has its mechanisms. Since PI3K activation is the main of PTEN (Y240 and Y315) important for PTEN phosphatase
activity and tumor inhibition function (Koul et al., 2002). Tyrosinemajor upstream signaling event leading to Akt phosphorylation
(Cantley, 2002), we examined whether trastuzumab induced phosphorylation of PTEN reduces the capacity of the PTEN C2
domain to bind to the cellular membrane (Lu et al., 2003). Sincerapid Akt dephosphorylation by inhibiting PI3K. However, PI3K
activity was not inhibited within 1 hr of trastuzumab treatment we observed increased membrane localization of PTEN by tras-
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Figure 1. Rapid Akt dephosphorylation and PTEN
activation by trastuzumab
A: Immunoblotting (IB) of ErbB2, Tyr1248-phos-
phorylated ErbB2 (p-ErbB2), phosphorylated Akt
(p-Akt), and total Akt in trastuzumab (, 2g/ml)
or control IgG-treated (, 2 g/ml) BT474 cells
and SKBr3 cells. -actin blot served as loading
controls in all IB experiments. All in vitro experi-
ments were repeated at least three times. Repro-
ducible representative results are shown.
B: PI3K assay after 2 g/ml of trastuzumab treat-
ment of SKBr3 cells for the indicated time. Lysates
were immunoprecipitated with the PY20 anti-
body followed by incubation in kinase buffer.
Numbers below the panel indicate relative PI3K
activity to untreated cells. IP with IgG served as
a control.
C: Trastuzumab transiently increased association
of the p85 subunit of PI3K with the ErbB2 complex.
ErbB2 immunoprecipitates and total cell lysates
from untreated or trastuzumab-treated (2g/ml)
cells were immunoblotted with indicated anti-
bodies.
D: Increased PTEN phosphatase activities in tras-
tuzumab-treated (2 g/ml) SKBr3 cells. Upper
right insert shows, from left to right, immuno-
precipitated PTEN proteins from untreated and
trastuzumab-treated (20 or 60 min) cells. Immu-
noprecipitates by rabbit IgG from trastuzumab-
treated cells were the negative control.
E: Trastuzumab increased membrane bound
PTEN in BT474 cells. PTEN protein in the cytosolic
pool (sol) and the membrane bound pool (mem)
of untreated () or trastuzumab-treated (,
2 g/ml) cell lysates were blotted with indicated
antibodies. E-cadherin and ErbB2 were mem-
brane protein markers.
F: Reduction of PTEN tyrosine phosphorylation
after trastuzumab treatment in BT474 cells. BT474
cells were treated without or with 2 g/ml of tras-
tuzumab for the indicated time. PTEN IP using the
A2B1 PTEN antibody was followed by IB with PY99
phosphotyrosine antibody (top). The membrane
was then stripped and reprobed with A2B1 PTEN
antibody to show the IP efficiency. IgG was used
as a negative control. Numbers below the panel
indicate relative levels of PTEN tyrosine phos-
phorylation with 0 min trastuzumab treatment
defined as 1.
tuzumab treatment in ErbB2-overexpressing cells, we investi- PTEN is an early molecular event after trastuzumab treatment
independent of ErbB2 downregulation and PI3K inhibition.gated whether this may result from reduced PTEN tyrosine
phosphorylation. We immunoprecipitated PTEN from untreated
or trastuzumab-treated BT474 cells with the A2B1 PTEN anti- Trastuzumab activates PTEN by inhibiting Src
body and immunoblotted with the PY99 phosphotyrosine anti- association with ErbB2
body (Figure 1F). Consistent with the notion that PTEN is func- To investigate how trastuzumab inhibits PTEN tyrosine phos-
tionally inactive in ErbB2-overexpressing cells (Lu et al., 1999), phorylation, we examined whether trastuzumab may inhibit Src
tyrosine kinase, since Src activation has recently been reportedwe found that PTEN is highly phosphorylated on tyrosine in
untreated BT474 cells. However, trastuzumab treatment rapidly to increase PTEN tyrosine phosphorylation (Lu et al., 2003).
Compared to untreated cells, trastuzumab treatment rapidlyreduced PTEN tyrosine phosphorylation in BT474 cells (Figure
1F), which paralleled the increased PTEN membrane localization inhibited Src kinase activity (Figure 2A) and rapidly reduced Src
phosphorylation on Y416 (Figure 2B), an indicator of Src activityand PTEN activation by trastuzumab in these cells (Figures
1D and 1E). Thus, trastuzumab induces PTEN activation by (Frame, 2002). Reduced Src-Y416 phosphorylation corre-
sponded to reduced PTEN tyrosine phosphorylation (Figure 2B).increasing the translocation of PTEN from the cytoplasm to the
membrane through reducing the inhibitory tyrosine phosphory- Src is known to bind to ErbB2 and is thus activated in ErbB2-
overexpressing cancer cells (Belsches-Jablonski et al., 2001;lation of PTEN. Notably, these events occur before ErbB2 is
downregulated and PI3K is inhibited. Therefore, activation of Muthuswamy and Muller, 1995). To explore the mechanisms of
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Figure 2. Trastuzumab inhibited Src by dissociat-
ing Src from ErbB2, leading to reduced PTEN tyro-
sine phosphorylation
A: Trastuzumab treatment inhibits Src kinase ac-
tivity. BT474 cells were either untreated (N/T) or
treated with 2 g/ml trastuzumab (Ttzm) for the
indicated time. Src kinase activity was assayed
as in Experimental Procedures.
B: Trastuzumab treatment inhibits Src-Y416 phos-
phorylation. BT474 cells were treated similarly as
in Figure 1E. Cytosolic pool (sol) and membrane
bound pool (mem) lysates were blotted with the
indicated antibodies.
C: Trastuzumab induces Src dissociation from
ErbB2. BT474 cells were treated with trastuzumab
for the indicated time. Anti-ErbB2 and control
IgG immunoprecipitates were blotted with Src
antibody to detect ErbB2 bound Src.
D: The Src inhibitor PP2 decreases Src-Y416 phos-
phorylation. ErbB2, Src-Y416 phosphorylation,
and Src proteins were blotted with the indicated
antibodies in cell lysates.
E: Src inhibition results in PTEN dephosphorylation/
activation. ErbB2 transfectants of MDA-MB-435
cells (435.eB) were treated with 10% DMSO,
2 g/ml trastuzumab (Ttzm), 10 M PP2, or PBS
buffer. IP was done with PTEN antibody or control
IgG followed by IB of total PTEN and tyrosine-
phosphorylated PTEN.
F: Src activation leads to increased PTEN tyrosine
phosphorylation. Lysates from 435.eB and 435.eB
stably expressing constitutively activated Src
(eB/SrcCA) were immunoblotted with the indi-
cated antibodies. The Src kinase activities in both
cell lines were evaluated as in A.
G: Constitutive Src activation abolishes trastuzu-
mab-mediated PTEN membrane translocation.
435.eB and eB/SrcCA cells were untreated ()
or treated () with trastuzumab. The membrane
bound pool of cell lysates was blotted with indi-
cated antibodies.
trastuzumab-mediated Src inhibition, we examined whether Src the PTEN membrane translocation in the 435.eB cells, PTEN
membrane translocation by trastuzumab in the eB/SrcCA cellsbinding to ErbB2 is inhibited by trastuzumab treatment in BT474
cells. Trastuzumab induced a very rapid and dramatic reduction expressing constitutively activated Src was less effective (Figure
2G). Together, our data indicate that trastuzumab treatmentof ErbB2 bound Src (Figure 2C), indicating that trastuzumab
inhibited Src activity in ErbB2-overexpressing cells most likely inhibits Src binding to ErbB2 in ErbB2-overexpressing breast
cancer cells, thus inhibiting Src kinase activity, which leads toby inhibiting Src binding to ErbB2.
To further confirm that Src inhibition can reduce PTEN tyro- reduced PTEN tyrosine phosphorylation and increased PTEN
membrane localization and activity.sine phosphorylation in ErbB2-overexpressing breast cancer
cells, we examined whether the Src kinase inhibitor PP2 may
reduce PTEN tyrosine phosphorylation in the ErbB2-overex- PTEN activation contributes to trastuzumab’s
antiproliferation functionpressing 435.eB breast cancer cells (Yu et al., 1998a). Com-
pared to the solvent 10% dimethyl sulfoxide (DMSO)-treated Trastuzumab is known to inhibit the growth of ErbB2-overex-
pressing breast cancer cells through the downregulation of435.eB cells, PP2 treatment effectively inhibited Src phosphory-
lation on Y416 (Figure 2D) and also dramatically reduced tyro- ErbB2 and the subsequent inhibition of its downstream PI3K-
Akt signaling pathway (Hudziak et al., 1989; Yakes et al., 2002).sine phosphorylation of PTEN, similar to trastuzumab’s effect
(Figure 2E). Contrarily, the eB/SrcCA cells, which are 435.eB Since we found that trastuzumab activates PTEN before ErbB2
is downregulated and before PI3K is inhibited, it is imperativecells stably expressing a constitutively activated Src (Chan et
al., 2003) and having higher levels of Src-Y416 phosphorylation to determine whether PTEN activation indeed caused the rapid
Akt dephosphorylation and contributes to the antiproliferationand Src activity, showed a dramatic increase of PTEN tyrosine
phosphorylation compared to the 435.eB cells (Figure 2F). Fur- function of trastuzumab. To achieve this, we transfected SKBr3
breast cancer cells with PTEN antisense (AS) oligonucleotidesthermore, although trastuzumab treatment effectively increased
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Figure 3. PTEN reduction by PTEN AS oligonucleo-
tides confers resistance to trastuzumab’s antipro-
liferative effects in vitro and in vivo
A: PTEN protein is reduced in SKBr3 cells trans-
fected with PTEN AS (25 nM) compared to
mock or mismatched (MIS) oligonucleotide-
transfected cells.
B: Trastuzumab-mediated Akt dephosphoryla-
tion is attenuated in PTEN AS-transfected SKBr3
cells. MIS or PTEN AS-transfected SKBr3 cells (as
in A) were treated with trastuzumab (2 g/ml)
for the indicated times, and cell lysates were
immunoblotted.
C: Trastuzumab inhibited cell proliferation less in
PTEN AS-treated SKBr3 cells compared to MIS-
transfected cells. MIS or PTEN AS-transfected
SKBr3 cells (as in A) were treated with trastuzu-
mab (2 g/ml) for 3 and 5 days. Cell mass was
determined by MTS assay. Percent cell number
represents % cell counts under each treatment
relative to untreated cells.
D: Similar cell growth in MIS- or PTEN AS-trans-
fected SKBr3 cells without trastuzumab. Percent
cell numbers represents % cell counts compared
to Day 1 (defined as 100%).
E: PTEN-reduced BT474 cells are more resistant
to trastuzumab plus paclitaxel than PTEN normal
cells but have a similar paclitaxel response to
PTEN normal cells. BT474 cells were transfected
with 25 nM MIS or PTEN AS, treated by paclitaxel
(1, 2, and 4 nM) without or with 2 g/ml of trastu-
zumab (Ttzm) for 3 days. Percent cell viability are
cell mass as a % of untreated MIS-transfected
cells.
F: PTEN expression is reduced in BT474 xenografts
injected with PTEN AS. BT474 cells were inocu-
lated into the mfp of female nude mice. After
tumors reached 150 mm3, MIS or PTEN AS were
injected intratumor (15 g/injection, twice a
week) for 1 week. Removed tumors were stained
with antibodies to PTEN and ErbB2.
G: PTEN-deficient BT474 xenografts are more re-
sistant to trastuzumab than PTEN normal BT474
xenografts. After 1 week of PTEN AS or MIS treat-
ment (as in F), mice were treated with trastuzu-
mab (10 mg/kg) or vehicle twice a week. The
arrows indicate the starting days of AS/MIS treat-
ment (AS) and trastuzumab/vehicle treatment
(Ttzm). The results shown are the mean tumor
volume  SE; *p  0.05.
(Butler et al., 2002), which effectively reduced endogenous (Figure 3C). We observed similar results in BT474 cells (Supple-
mental Figure S3). These data demonstrate that normal PTENPTEN expression compared to mock-transfected cells or cells
transfected with control mismatched (MIS) oligonucleotides levels are required for the antiproliferation function of trastuzu-
mab. Without trastuzumab treatment, PTEN reduction by PTEN(Figure 3A). Compared with MIS control-treated cells showing
rapid Akt dephosphorylation by trastuzumab (Figure 3B, top), AS alone had no significant effect on cell proliferation (Figure
3D), which was consistent with the similar Akt phosphorylationAkt dephosphorylation was attenuated in PTEN AS-treated cells
(Figure 3B, bottom). This indicates that PTEN is required for the levels in cells treated with PTEN AS alone to that treated with
MIS control (Figure 3B, time 0). That blocking PTEN only re-rapid Akt dephosphorylation by trastuzumab. To investigate
whether PTEN activation contributes to trastuzumab’s antiprolif- duced trastuzumab’s antiproliferative function but had no effect
on cells without trastuzumab treatment reiterated that PTENeration function, we compared cell growth between MIS control
and PTEN AS-transfected SKBr3 cells after trastuzumab treat- activity is important for trastuzumab function, which reconciles
well with our finding that PTEN is activated by trastuzumabment. PTEN AS-treated cells with reduced PTEN showed sig-
nificantly less growth inhibition by trastuzumab than MIS con- (Figures 1D–1F). Thus, PTEN reduction led to resistance to the
antiproliferation effect of trastuzumab in these cells.trol-transfected SKBr3 cells having normal PTEN expression
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Trastuzumab is mostly used in combination with other che-
motherapeutics in the clinic (Slamon et al., 2001). Therefore,
we further examined whether PTEN reduction may confer breast
cancer cell resistance to trastuzumab plus paclitaxel chemo-
therapy. We transfected BT474 cells with PTEN AS or MIS
control oligonucleotides, then treated them with or without tras-
tuzumab (2 g/ml) plus different concentrations of paclitaxel (1,
2, and 4 nM) and measured cell viability 3 days later. MIS control-
treated cells with normal PTEN expression showed significant
growth inhibition by trastuzumab plus paclitaxel (p  0.05),
whereas PTEN AS-transfected cells were not inhibited (Figure
3E, top). However, paclitaxel alone without trastuzumab showed
no statistically significant difference in cell viability between
PTEN AS- and MIS control-transfected cells (Figure 3E, bottom),
indicating that PTEN status does not significantly impact breast
cancer cell sensitivity to paclitaxel but specifically impacts tras-
tuzumab sensitivity. These results indicate that breast cancer
cells with reduced PTEN are resistant to growth inhibition by
trastuzumab as a single agent (Figure 3C) as well as in combina-
tion with paclitaxel (Figure 3E).
PTEN deficiency contributes to trastuzumab
resistance in vivo
To investigate if PTEN deficiency may confer breast cancer cell
resistance to trastuzumab in vivo, we injected a tumorigenic
subline of BT474 cells into the mammary fat pad (mfp) of athymic
nude mice. When tumor xenografts reached 150 mm3, we
injected PTEN AS or MIS oligonucleotides into the tumor xeno-
grafts. One week later, we treated mice with trastuzumab (10
mg/kg) or vehicle twice per week. PTEN expression in tumor
xenografts was effectively inhibited by PTEN AS when ErbB2
expression remained the same (Figure 3F). Trastuzumab only
inhibited MIS control-treated tumors expressing normal PTEN,
but not PTEN AS-treated tumors with reduced PTEN (Figure
3G). Without trastuzumab treatment, PTEN AS- and MIS-treated
tumors had similar tumor growth rates (Figure 3G). These results
demonstrated that PTEN reduction confers breast tumor xeno- Figure 4. PI3K inhibitors enhance trastuzumab’s antiproliferation function in
PTEN-reduced BT474 cells in vitro and in vivografts resistance to trastuzumab’s antitumor function.
A: BT474 cells were treated with MIS or PTEN AS oligonucleotides as in Figure
3A. Cells were then treated with trastuzumab (Ttzm, 2 g/ml), LY294002 (LY,PI3K inhibitors rescue PTEN loss-induced
0.8 M), or trastuzumab plus LY294002 (Ttzm  LY) for 3 days. Percent inhibi-trastuzumab resistance
tion is % growth reduction under each treatment relative to untreated cells.
The above data clearly demonstrate that PTEN deficiency con- **p  0.01.
fers trastuzumab resistance in breast cancer. In search of strate- B: BT474 cells were treated with MIS or PTEN AS as in Figure 3A. Cells were
then treated with trastuzumab (2 g/ml), Wortmannin (WN, 1 M), or tras-gies for overcoming trastuzumab resistance from the loss of
tuzumab plus Wortmannin (Ttzm  WN) for 3 days. Percent inhibition isPTEN, we reasoned that since PI3K antagonizes PTEN function,
% growth reduction under each treatment relative to untreated cells.inactivation of PI3K may rescue trastuzumab resistance from
**p  0.01.
PTEN deficiency. We investigated whether PI3K inhibitors that C: BT474 xenografts were treated with PTEN AS as in Figure 3G. Mice were
are known to quickly induce Akt dephosphorylation in ErbB2- treated with trastuzumab (10 mg/kg) twice a week or/and LY294002 (100
mg/kg) 3 times a week for 3 weeks. The arrows indicate the starting daysoverexpressing cells may reverse trastuzumab resistance in
of AS treatment (AS) and trastuzumab and/or LY294002 treatment (Ttzm,PTEN-deficient breast cancer cells (Xiong et al., 2001). We trans-
LY). The results are the mean tumor volume  SE. *p  0.05.
fected BT474 cells with MIS and PTEN AS oligonucleotides, then
treated them with trastuzumab, the PI3K inhibitor LY294002, or
trastuzumab plus LY294002. We then determined cell viability
3 days later (Figure 4A). The MIS-treated cells are more sensitive mannin, in combination with trastuzumab, also inhibited PTEN
to trastuzumab-mediated growth inhibition than the PTEN AS- AS-treated BT474 cells significantly better than either treatment
treated cells, and the combination treatment inhibited the viabil- alone (p  0.01), whereas the combination had a similar inhibi-
ity of MIS-treated cells slightly better than trastuzumab alone tory effect as trastuzumab alone in MIS-treated cells (Figure 4B).
or LY294002 alone (p  0.05). However, the LY294002 plus In vivo, trastuzumab combined with the PI3K inhibitor LY294002
trastuzumab combination inhibited cell viability significantly bet- was also significantly (p 0.05) more effective than trastuzumab
ter than trastuzumab alone or LY294002 alone in PTEN AS- alone or LY294002 alone in inhibiting PTEN AS-treated BT474
tumor xenografts in mice (Figure 4C). These results indicatetreated cells (p  0.01). Similarly, another PI3K inhibitor, Wort-
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that PI3K inhibitors could overcome trastuzumab resistance in
PTEN-deficient breast cancer cells.
Patients with PTEN-deficient breast cancers have
a poor clinical response to trastuzumab
To explore the clinical significance of PTEN status in predicting
response to trastuzumab-based therapy in patients, we evalu-
ated PTEN expression in 47 ErbB2-overexpressing primary
breast carcinomas from patients who subsequently developed
metastatic breast cancer and received trastuzumab plus taxane
(paclitaxel or docetaxel) therapy (Esteva et al., 2002; Seidman
et al., 2001). As controls, we evaluated PTEN expression in
primary breast carcinomas not selected for ErbB2 overexpres-
sion from 37 patients who subsequently developed metastatic
breast cancer and received taxane without trastuzumab
(Holmes et al., 1991; Valero et al., 1995). Immunohistochemical
staining using PTEN antibodies revealed that PTEN expression
in these tumors was heterogeneous with different intensities.
Thus, PTEN expression levels were semiquantified using immu-
noreactive scores (IRS) calculated by multiplying the percentage
of PTEN-positive cells (scored 0 to 4) with the PTEN staining
intensity (1 to 3) (Chui et al., 1996). IRS of 0 to 12 represents
PTEN staining from a nondetectable level in PTEN-lost tumors to
full expressions in normal individuals (Figure 5A). We observed
PTEN loss (IRS  9) in 36.2%–43.2% of the tumors examined
(17/47 and 16/37), which is consistent with previous reports
on loss of PTEN expression in 40% breast cancers using
immunohistochemistry (IHC) staining (Depowski et al., 2001;
Perren et al., 1999). Remarkably, among the 47 breast cancer
patients who received trastuzumab plus taxane, patients with
PTEN-deficient tumors (IRS 0–6) had significantly lower com-
plete and partial response (CRPR) rates to trastuzumab plus
taxane therapy than patients with PTEN-positive tumors (35.7%
versus 66.7%, p  0.05) (Figure 5B, left). Using more stringent
criteria for PTEN loss (IRS  4), patients with PTEN-negative
tumors demonstrated a striking, highly significant (p  0.01)
Figure 5. Patients with PTEN-deficient breast tumors have a poor responseworse response to trastuzumab plus taxane therapy than pa- to trastuzumab-based therapy
tients with PTEN-positive tumors (11.1% versus 65.8% CRPR)
A: PTEN expression patterns in human breast tumors. ErbB2-overexpressing
(Figure 5B, right). Furthermore, we identified a statistically sig- (IHC 3, 2, and/or FISH-positive) primary breast carcinomas were col-
nificant trend suggesting that the probability of response to lected from 47 patients who subsequently received trastuzumab plus tax-
ane (paclitaxel or docetaxel) on IRB-approved clinical trials conducted attrastuzumab decreases as PTEN IRS decreases (p 0.01) (Sup-
the UT M.D. Anderson Cancer Center (Esteva et al., 2002; Seidman et al.,plemental Figure S4). However, among the 37 patients treated
2001). PTEN expression in these tumors was examined by IHC and semiquan-by taxane without trastuzumab, patients with PTEN-deficient tified using immunoreactive scores (IRS, see Experimental Procedures). Rep-
tumors had similar response (CRPR) rates to those with resentative tumor PTEN stainings (IRS 12, 9, 3, and 0) are shown.
B: Worse responses to trastuzumab-based therapy in patients withPTEN-positive tumors (p  0.40 when PTEN loss is defined as
PTEN-deficient tumors than those with PTEN-positive tumors. PTEN deficiencyIRS 0–6; p  0.74 when PTEN loss is defined as IRS  4;
were defined by PTEN IRS  9 (left panel) or  4 (right panel). *p  0.05;Supplemental Figure S5). These data clearly demonstrate that
**p  0.01. Complete response (CR), partial response (PR), stable disease
PTEN loss does not confer breast cancer resistance to taxane (SD), and progressive disease (PD). n, number of patients studied.
but specifically to trastuzumab. To confirm that PTEN is a spe- C: Trastuzumab plus taxane response rates in patients with ErbB2 FISH-posi-
tive and/or IHC 3 breast cancers versus patients with ErbB2 FISH-negativecific marker for trastuzumab response, we examined whether
and/or IHC 2 cancers (p  0.05).Ki67, a known prognostic marker for breast cancer (Faneyte et
D: Among patients with ErbB2 FISH-positive and/or IHC 3 breast cancers,al., 2003), may predict trastuzumab response in patients who patients with PTEN-deficient tumors responded less to trastuzumab-based
received trastuzumab plus taxane. Ki67 did not correlate with therapy than those with PTEN normal tumors. **p  0.01. Data (A–D) were
obtained in a double blind manner.clinical responses to trastuzumab plus taxane treatment (Sup-
plemental Figure S6). It has been reported that patients with
ErbB2 FISH-positive and/or IHC 3 breast cancers respond
to trastuzumab better than patients with ErbB2 FISH-negative
significant (Figure 5C). However, among patients with ErbB2and/or 2 cancers (Vogel et al., 2002). Although we see a similar
FISH-positive and/or IHC 3 breast cancers, patients withtendency (59% for FISH-positive and/or IHC 3 versus 37%
PTEN-deficient tumors (IRS 0–3) had significantly lower re-for FISH-negative and/or IHC 2) among the 47 patients treated
with trastuzumab plus taxane, the difference was not statistically sponse (CRPR) rates than patients with PTEN-positive tumors
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(12.5% versus 71%, p  0.01) (Figure 5D). The data indicate normal PTEN, and the difference was statistically highly signifi-
that PTEN status is a unique and powerful marker for predicting cant (p  0.01) even in this small cohort. Thus, the PTEN status
clinical response to trastuzumab-based therapy. of ErbB2-overexpressing breast tumors may be used as a pre-
dictive factor for patients’ trastuzumab response in the clinic.
Discussion PTEN loss in an ErbB2-overexpressing breast tumor can also
serve as an indication that the patient needs combination ther-
Trastuzumab has been a model of a rationally designed, highly apy with PI3K inhibitors to overcome the PTEN loss-mediated
specific, targeted cancer therapy and has brought valuable ther- trastuzumab resistance to receive the maximum therapeutic
apeutic benefits to patients with ErbB2-overexpressing cancers benefit of trastuzumab. Large-scale clinical investigations will
(Albanell and Baselga, 2001; Dickman, 1998). However, the lim- be performed to further validate these ideas.
ited response rates of trastuzumab, even in patients with tumors Loss of PTEN function from PTEN mutations was reported
expressing very high levels of ErbB2, raises questions on the in 5%–10% of human breast cancers, and PTEN haploinsuffi-
mechanisms of trastuzumab function (other than those related ciency due to loss of heterozygosity at the PTEN locus can be
to the inhibition of ErbB2 signaling) and on the mechanisms of found in nearly 50% of breast tumors (Li et al., 1997; Teng et
trastuzumab resistance in patients. Here, we report that the al., 1997). In addition, epigenetic downmodulation of PTEN has
phosphatase function of the tumor suppressor PTEN is rapidly also been reported (Mutter et al., 2000; Whang et al., 1998).
activated by trastuzumab before it downregulates the ErbB2 Consistent with these reports, we identified PTEN deficiencies
receptor. This finding led to the new concept that PTEN activa- in 40% of breast cancers in our two small cohorts, indicating
tion is a novel mechanism that contributes to trastuzumab’s that the PTEN loss rate is similar among patients with ErbB2-
antitumor activity independent of its well-known function of overexpressing tumors and breast cancer patients in general.
ErbB2 downregulation. We also found that trastuzumab acti- Our finding that PTEN deficiency confers trastuzumab resis-
vated PTEN by inhibiting PTEN tyrosine phosphorylation tance in ErbB2-overexpressing breast cancers could directly
through reducing the ErbB2 receptor bound Src—thus inhibiting impact the clinical management of these patients with
Src, a tyrosine kinase for PTEN (Lu et al., 2003). This indicates PTEN-deficient tumors. In light of this, we have shown that PI3K
a functional crosstalk between the ErbB2 receptor and the PTEN inhibitors could overcome PTEN loss-induced trastuzumab re-
tumor suppressor in breast cancer cells via Src: Src plays impor- sistance in ErbB2-overexpressing breast cancer cells in vitro
tant oncogenic functions (e.g., inactivates PTEN) when bound and in vivo. This suggests that members of the PI3K pathway, as
to and activated by overexpressed ErbB2, whereas trastuzumab well as PTEN, are molecular targets for overcoming trastuzumab
dissociates Src from ErbB2, inhibits Src, and thus activates resistance. These new insights will guide the future development
PTEN, which contributes to the trastuzumab antitumor function. of agents for overcoming trastuzumab resistance and novel
This newly identified mechanism of trastuzumab function targeted cancer therapies to benefit cancer patients.
clearly indicates that trastuzumab responsiveness depends not
only on the downregulation of ErbB2 and the inhibition of ErbB2- Experimental procedures
related downstream events, but also on the status of PTEN.
Antibodies and reagentsIndeed, our data from cultured breast cancer cell lines, mouse
PTEN antibodies were from Santa Cruz Biotechnology (A2B1, Santa Cruz,tumor xenografts, and most importantly, from clinical samples
CA) and Lab Vision Corp. (Ab2, Fremont, CA); antibodies to Akt, phospho-of breast cancer patients consistently demonstrated that PTEN
Akt, and Y416-phosphorylated Src were from Cell Signaling Technology
deficiency is a molecular mechanism that confers ErbB2-over- (Beverly, MA); antibodies to ErbB2 and v-Src (Ab-1) were from Calbiochem
expressing breast cancers resistance to trastuzumab-based (La Jolla, CA); antibodies to the 85 kDa subunit of PI3K, phospho-ErbB2,
therapy and that PTEN loss was associated with trastuzumab and phospho-tyrosine (4G10) were from Upstate Biotechnology, Inc. (Wal-
tham, MA); antibody to phosphotyrosine (PY20) was from BD Biosciencesresistance in patients. The response rate of trastuzumab as a
(San Diego, CA); and trastuzumab was from Genentech, Inc. (San Francisco,single agent was reported higher in patients with ErbB2 FISH-
CA). LY294002 was from Cell Signaling Technology; Wortmannin, PP2, andpositive and/or IHC 3 breast cancers than in patients with
AG1879 were from Calbiochem; Enolase was from was Sigma (St. Louis,
ErbB2 FISH-negative and/or 2 tumors (Vogel et al., 2002). We MO); and taxol was from Bristol Myers-Squibb (Princeton, NJ). Src/CA mu-
observed a similar, but not significant, trend in our small cohort tant expression vector was provided by Dr. David Shalloway (Cornell Uni-
of 47 patients treated with trastuzumab plus taxane. Notably, versity).
among these 47 patients, there was an even smaller cohort of
Cell culturepatients (n 39) with ErbB2 FISH-positive and/or IHC 3 breast
SKBr3 cells were from the American Type Culture Collection (Manassas,cancers, who, based on the previous reports (Vogel et al., 2002),
VA) and maintained in McCoy’s 5A containing 15% fetal bovine serum (FBS),should have better response rates to trastuzumab. However,
and the BT474 subline was from Dajun Yang (Georgetown University) andamong the 39 patients, those with PTEN-negative tumors had
maintained in DMEM/F12 with 10% FBS. Both lines have the wild-type PTEN
significantly worse response to trastuzumab-based therapy gene (Li et al., 1997).
than those with PTEN-positive tumors (p  0.004). Thus, the
PTEN status seems to be a more sensitive and specific predictor PI3K activity assay
PI3K activities were determined in the PY20 antibody immunoprecipitatesfor trastuzumab-based therapy.
of untreated or trastuzumab-treated lysates as we did previously (Tan et al.,Insulin-like growth factor-I receptor (IGF-IR) signaling was
1999).implicated in trastuzumab resistance, but it has not been vali-
dated with clinical data (Lu et al., 2001). Remarkably, our finding Src kinase assay
that PTEN deficiency confers trastuzumab resistance is strongly Equal amounts of cell lysates were immunoprecipitated with anti-Src anti-
supported by clinical data that patients with PTEN-deficient body (OP07, Oncogene Research Products, Boston, MA). The precipitates
were washed and incubated with 250 g/ml enolase, 2 Ci of [-32P]ATP,tumors did not respond to trastuzumab as well as those with
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and 3 l of 100 mM ATP in 40 l of kinase buffer. After 30 min at 37	C, the in saline was delivered by multiple intratumor injection as described (Urano
et al., 2002). A week later, mice received trastuzumab (10 mg/kg) or vehiclesamples were boiled in 15 l of 6
SDS sample buffer for 5 min and then
subjected to SDS-PAGE. The 32P-labeled enolase was visualized by autoradi- (PBS) twice/week, combined with LY294002 (100 mg/kg) or vehicle (DMSO)
three times/week. Tumor diameters were serially measured with calipersography.
and tumor volumes calculated: volume  width2 
 length/2. Each treatment
group had 8–12 mice. Unpaired Student’s t test was used to assess statisticalAntisense delivery in vitro
significance.Antisense (AS) oligonucleotides against PTEN (ISIS 116847: 5-CTGCTAGC
CTCTGGATTTGA-3) and control oligonucleotides (ISIS 116848: 5-CTTCTG
Patient samplesGCATCCGGTTTAGA-3) have been described (Butler et al., 2002). Cells
ErbB2-overexpressing primary breast carcinomas were collected from 47were plated in 100 mm dishes at 30% confluence and transfected with
patients who subsequently developed metastatic breast cancer and receivedoligonucleotides (12.5 nM for BT474 and 25 nM for SKBr3 cells) twice using
trastuzumab plus taxane (paclitaxel or docetaxel) (Esteva et al., 2002; Seid-Oligofectamine (Life Technologies, Rockville, MD) 24 and 72 hr postplating.
man et al., 2001). Primary breast carcinomas not selected for ErbB2-overex-Cells were replated for individual assays described in this report 96 hr
pressing tumors from 37 patients who subsequently developed metastaticpostplating. PTEN expression was determined 120 hr postplating (Figure 3A).
breast cancer and received taxane without trastuzumab were collected as
controls (Holmes et al., 1991; Valero et al., 1995). The 47 patients wereCell viability assay
treated between 1998 and 2001 and the 37 patients were treated between1–5 
 103 cells/well were seeded in 96-well plates after transfection. Viable
1990 and 1991 under IRB-approved clinical trials at The University of Texascells were determined by CellTiter 96 AQueous Non-Radioactive Cell Prolifer-
M.D. Anderson Cancer Center. Association between clinical response toation Assay (Promega, Madison, WI).
therapy and PTEN status was tested using chi-square and Fisher’s tests.
Cell lysates preparation, IP, and IB
PTEN IHC and evaluationCells at 70%–80% confluence were treated with each reagent indicated in
Slides (4 m) of formalin-fixed, paraffin-embedded tissue sections werethe individual experiments. For PTEN phosphotyrosine immunoblots, ErbB2
incubated with PTEN antibody (Ab-2, 1:500) as described (Podsypanina etIP, and Src IP, cells were treated with 30 M pervanadate for 10 min as
al., 2001). IHC was performed with LSAB2 kit (DAKO, Carpinteria, CA),described (Lu et al., 2003). Cells were washed with PBS and lysed in IP
color development with 3-3-diaminobenzidine, and counterstaining withbuffer with protease inhibitor cocktail (Sigma). IP and IB were performed as
hematoxylin. PTEN expression level was scored semiquantitatively baseddescribed (Yu et al., 1998b).
on staining intensity and distribution using the immunoreactive score (IRS)
as described (Chui et al., 1996; Friedrichs et al., 1993) and as following:PTEN phosphatase assay
IRS  SI (staining intensity) 
 PP (percentage of positive cells). SI wasPTEN phosphatase activity was measured as described with minor modi-
determined as 0  negative; 1  weak; 2  moderate; and 3  strong. PPfications (Georgescu et al., 1999). Lysates were precleared with protein
was defined as 0, 1%; 1, 1%–10%; 2, 11%–50%; 3, 51%–80%; andG-agarose beads to eliminate trastuzumab used as treatments prior to IP
4, 80% positive cells. Ten visual fields from different areas of each tumorwith PTEN antibodies (Ab-2 or A2B1). After IP, the beads were washed once
were used for the IRS evaluation. Negative control slides without primaryin lysis buffer; five times in low-stringency buffer containing 20 mM HEPES
antibody were included for each staining. Normal breast epithelium or vascu-(pH 7.7), 50 mM NaCl, 0.1 mM EDTA, and 2.5 mM MgCl2; and once in
lar endothelium known to express normal PTEN was used as positive con-phosphatase assay buffer lacking PIP3. Assays were performed for 40 min
trols.at 37	C in 50 l buffer containing 100 mM Tris-HCl (pH 8.0), 10 mM DTT,
and 100 M water-soluble diC8-PIP3 substrate (Echelon, Salt Lake City, UT)
ErbB2 statusin a 96-well plate. Release of phosphate from substrate was measured
ErbB2 gene amplification in patients’ samples was assayed by fluorescenceusing Biomol Green Reagent (Biomol Research Laboratories, Inc., Plymouth
in situ hybridization (FISH) using PathVysion FISH assay (Vysis, Inc., IL).Meeting, PA).
ErbB2 protein was determined by IHC as described (Jacobs et al., 1999).
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Analysis of internalization using flow cytometry
Immunofluorescent flow cytometry was performed as described (Drebin et
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